Thomas Kruse
Biography & Research Background
Thomas Kruse is a lead scientist at Novo Nordisk A/S in Måløv, Denmark. He played a central role in the chemical development and structural engineering of cagriniltide, leading the structure-activity relationship (SAR) efforts to create a long-acting, stable amylin analog that activates both amylin receptors and the calcitonin receptor while overcoming the instability and fibrillation issues of native human amylin. His key publications include "Development of Cagrilintide, a Long-Acting Amylin Analogue" (2021, Journal of Medicinal Chemistry) and "NN1213 – A Potent, Long-Acting, and Selective Analog of Human Amylin" (2024, Journal of Medicinal Chemistry). Thomas Kruse is being referenced as one of the leading scientists involved in cagriniltide research. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
Thomas Kruse is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Thomas Kruse is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.